Live symbol workspace

D market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $62.77

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$59.63

Resistance

$65.91

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$62.77

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for D skewed neutral (2 of 4 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

▲ 0.3 pts vs previous week

Avg confidence across 98 calls in the last 7 days

What sources say

Neutral 2 articles

First US LNG Shipment to China in a Year to Be Re-Exported

Eastern US Heat Wave Starts to Retreat While Raising Storm Risk

Bullish 1 article

U.S. LNG Exporter Reaps Windfall as Middle East Turmoil Drives Fees Higher

Bearish 1 article

Dip in U.S. LNG Imports to EU Spells Trouble for Trade Deal

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

D News Intelligence (813 articles)

AI-curated news influencing D price, sentiment, and trend

Explore All D News with AI Analysis

Cryptocurrency

5 months, 1 week ago

Figure is debuting its tokenized stock along with upsized $150 million offering

The FGRD token represents common shares of the company issued natively onchain with instant settlement and built-in lending tools.

Impact on D: Market impact analysis based on bullish sentiment with 90% confidence.

Figure is launching its tokenized stock, FGRD, as part of a $150 million offering, marking … High (90%)

View full analysis →

CoinDesk 90% confidence

Economy

5 months, 1 week ago

Three Top Dividend Stocks To Consider

As February begins, U.S. stock indexes have shown strength, with the Dow Jones Industrial Average adding 515 points and the …

Impact on D: Market impact analysis based on bullish sentiment with 80% confidence.

U.S. stock indexes show strength, making dividend stocks an attractive option for investors seeking balance … High (80%)

View full analysis →

Yahoo Finance 80% confidence

Economy

5 months, 1 week ago

2 No-Brainer Dividend Stocks to Buy Right Now

If you are looking to maximize the dividends you generate, you'll want to look at Realty Income and General Mills …

Impact on D: Market impact analysis based on bullish sentiment with 90% confidence.

The article suggests investing in Realty Income and General Mills for maximizing dividend returns, highlighting … High (90%)

View full analysis →

Yahoo Finance 90% confidence

Economy

5 months, 1 week ago

Ananym Capital Buys Another $11 Million of LKQ Amid Stock's 26% Pullback

LKQ is a global distributor of automotive replacement parts serving repair shops and dealerships across North America and Europe.

Impact on D: Market impact analysis based on bullish sentiment with 80% confidence.

Ananym Capital has invested an additional $11 million in LKQ, a global distributor of automotive … High (80%)

View full analysis →

Yahoo Finance 80% confidence

Economy

5 months, 1 week ago

What China Partnerships Would Mean for Ford Stock.

What are investors to make of reports that Ford Motor discussed Chinese joint ventures with the White House.

Impact on D: Market impact analysis based on neutral sentiment with 65% confidence.

Reports of Ford Motor discussing Chinese joint ventures with the White House may have a … Medium (65%)

View full analysis →

Yahoo Finance 65% confidence

Economy

5 months, 1 week ago

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Impact on D: Market impact analysis based on bearish sentiment with 90% confidence.

Biotech company Arcellx has been sold for $26 million due to its poor stock performance … High (90%)

View full analysis →

Yahoo Finance 90% confidence